Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in:

Open Access 16-05-2024 | Cardiomyopathy | Echocardiography (JM Gardin and AH Waller, Section Editors)

The Role of Multimodality Imaging in Cardiomyopathy

Authors: Jonathan A. Pan, Amit R. Patel

Published in: Current Cardiology Reports | Issue 7/2024

Login to get access

Abstract

Purpose of Review

There has been increasing use of multimodality imaging in the evaluation of cardiomyopathies.

Recent Findings

Echocardiography, cardiac magnetic resonance (CMR), cardiac nuclear imaging, and cardiac computed tomography (CCT) play an important role in the diagnosis, risk stratification, and management of patients with cardiomyopathies.

Summary

Echocardiography is essential in the initial assessment of suspected cardiomyopathy, but a multimodality approach can improve diagnostics and management. CMR allows for accurate measurement of volumes and function, and can easily detect unique pathologic structures. In addition, contrast imaging and parametric mapping enable the characterization of tissue features such as scar, edema, infiltration, and deposition. In non-ischemic cardiomyopathies, metabolic and molecular nuclear imaging is used to diagnose rare but life-threatening conditions such amyloidosis and sarcoidosis. There is an expanding use of CCT for planning electrophysiology procedures such as cardioversion, ablations, and device placement. Furthermore, CCT can evaluate for complications associated with advanced heart failure therapies such as cardiac transplant and mechanical support devices. Innovations in multimodality cardiac imaging should lead to increased volumes and better outcomes.
Literature
1.
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.CrossRef
2.
Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2021;6(8):952–6.PubMedCrossRef
3.
Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on heart failure in the United States: the medical expenditure panel survey 2009–2018. JACC Heart Fail. 2022;10(8):571–80.PubMedPubMedCentralCrossRef
4.
Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18(1):74.PubMedPubMedCentralCrossRef
5.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.PubMedCrossRef
6.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.PubMed
7.
8.
Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1–64.PubMedCrossRef
9.
10.
Muraru D, Cecchetto A, Cucchini U, Zhou X, Lang RM, Romeo G, et al. Intervendor consistency and accuracy of left ventricular volume measurements using three-dimensional echocardiography. J Am Soc Echocardiogr. 2018;31(2):158–168 e1.PubMedCrossRef
11.
Bhatia RS, Farkouh M, Ivers N, Yin XC, Myers D, Nesbitt G, et al. Improving the appropriate use of transthoracic echocardiography-the results of the echo WISELY trial. Eur Heart J. 2017;38:1089–1089.CrossRef
12.
Paulraj S, Kumar PA, Byrnes S, Ojha N, Singh A, Raj V. A quality improvement initiative for echocardiogram ordering patterns in an Academic Hospital. Cureus J Med Sci. 2024;16(1):e52717.
13.
Mehta M, Jacobson T, Peters D, Le E, Chadderdon S, Allen AJ, et al. Handheld ultrasound versus physical examination in patients referred for transthoracic echocardiography for a suspected cardiac condition. JACC Cardiovasc Imaging. 2014;7(10):983–90.PubMedCrossRef
14.
15.
16.
He BY, Kwan AC, Cho JH, Yuan NL, Pollick C, Shiota T, et al. Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature. 2023;616(7957):520–4.PubMedPubMedCentralCrossRef
17.
Liu BH, Chang H, Yang D, Yang FF, Wang QS, Deng YJ, et al. A deep learning framework assisted echocardiography with diagnosis, lesion localization, phenogrouping heterogeneous disease, and anomaly detection. Sci Rep. 2023;13(1):3.PubMedPubMedCentralCrossRef
18.
Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, et al. Reference ranges (“normal values”) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020;22(1):87.PubMedPubMedCentralCrossRef
19.
Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani A, Dorian P, et al. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. J Cardiovasc Magn Reson. 2012;14(1):69.PubMedPubMedCentralCrossRef
20.
• Champ-Rigot L, Gay P, Seita F, Benouda L, Morello R, Pellissier A, et al. Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2020;22(1):48. Findings from this study suggest that CMR is more accurate for predicting adverse outcomes when compared to echocardiogram in patients referred for primary prevention ICD.PubMedPubMedCentralCrossRef
21.
Zhao L, Lu A, Tian J, Huang J, Ma X. Effects of different LVEF assessed by echocardiography and CMR on the diagnosis and therapeutic decisions of cardiovascular diseases. Front Physiol. 2020;11:679.PubMedPubMedCentralCrossRef
22.
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.PubMedCrossRef
23.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):3022–55.PubMedCrossRef
24.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85.PubMedCrossRef
25.
Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541–9.PubMedCrossRef
26.
Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761–73.PubMedCrossRef
27.
Ikeda U, Minamisawa M, Koyama J. Isolated left ventricular non-compaction cardiomyopathy in adults. J Cardiol. 2015;65(2):91–7.PubMedCrossRef
28.
Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639–46.PubMedCrossRef
29.
Shemisa K, Li J, Tam M, Barcena J. Left ventricular noncompaction cardiomyopathy. Cardiovasc Diagn Ther. 2013;3(3):170–5.PubMedPubMedCentral
30.
Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101–5.PubMedCrossRef
31.
Grothoff M, Pachowsky M, Hoffmann J, Posch M, Klaassen S, Lehmkuhl L, et al. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol. 2012;22(12):2699–709.PubMedPubMedCentralCrossRef
32.
Kohli SK, Pantazis AA, Shah JS, Adeyemi B, Jackson G, McKenna WJ, et al. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J. 2008;29(1):89–95.PubMedCrossRef
33.
Tian T, Liu Y, Gao L, Wang J, Sun K, Zou Y, et al. Isolated left ventricular noncompaction: clinical profile and prognosis in 106 adult patients. Heart Vessels. 2014;29(5):645–52.PubMedCrossRef
34.
Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65(2):384–98.PubMedCrossRef
35.
Norman M, Simpson M, Mogensen J, Shaw A, Hughes S, Syrris P, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005;112(5):636–42.PubMedCrossRef
36.
Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation. 2003;108(24):3000–5.PubMedCrossRef
37.
te Riele AS, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson. 2014;16(1):50.CrossRef
38.
Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol. 2020;319:106–14.PubMedCrossRef
39.
Rastegar N, Burt JR, Corona-Villalobos CP, Te Riele AS, James CA, Murray B, et al. Cardiac MR findings and potential diagnostic pitfalls in patients evaluated for arrhythmogenic right ventricular cardiomyopathy. Radiographics. 2014;34(6):1553–70.PubMedCrossRef
40.
Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16(1):14–22.PubMedCrossRef
41.
Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250–8.PubMedCrossRef
42.
Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72(8):857–70.PubMedCrossRef
43.
Velangi PS, Choo C, Chen KHA, Kazmirczak F, Nijjar PS, Farzaneh-Far A, et al. Long-term embolic outcomes after detection of left ventricular thrombus by late gadolinium enhancement cardiovascular magnetic resonance imaging a matched Cohort Study. Circ Cardiovasc Imaging. 2019;12(11):1.CrossRef
44.
Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(10 Pt A):1180–93.PubMedPubMedCentralCrossRef
45.
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53.PubMedCrossRef
46.
McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54–9.PubMedCrossRef
47.
Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896–908.PubMedCrossRef
48.
Coleman GC, Shaw PW, Balfour PC Jr, Gonzalez JA, Kramer CM, Patel AR, et al. Prognostic value of myocardial scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10(4):411–20.PubMedCrossRef
49.
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.PubMedCrossRef
50.
White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143–56.PubMedPubMedCentralCrossRef
51.
Torreao JA, Ianni BM, Mady C, Naia E, Rassi CH, Nomura C, et al. Myocardial tissue characterization in Chagas’ heart disease by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015;17:97.PubMedPubMedCentralCrossRef
52.
Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14(1):11.PubMedPubMedCentralCrossRef
53.
Bravo PE, Luo HC, Pozios I, Zimmerman SL, Corona-Villalobos CP, Sorensen L, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016;17(3):293–300.PubMedCrossRef
54.
Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2332–44.PubMedPubMedCentralCrossRef
55.
56.
Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol. 1983;52(1):184–8.PubMedCrossRef
57.
Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging. 2012;5(6):596–603.PubMedPubMedCentralCrossRef
58.
Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475–84.PubMedCrossRef
59.
Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52(19):1574–80.PubMedCrossRef
60.
Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging. 2016;9(1):67–81.PubMedCrossRef
61.
Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–44.PubMedCrossRef
62.
Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.PubMedCrossRef
63.
Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J, et al. Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. JACC Cardiovasc Imaging. 2016;9(1):54–63.PubMedCrossRef
64.
Chen W, Doeblin P, Al-Tabatabaee S, Klingel K, Tanacli R, Jakob Weiss K, et al. Synthetic extracellular volume in cardiac magnetic resonance without blood sampling: a reliable tool to replace conventional extracellular volume. Circ Cardiovasc Imaging. 2022;15(4):e013745.PubMedPubMedCentralCrossRef
65.
Raucci FJ Jr, Parra DA, Christensen JT, Hernandez LE, Markham LW, Xu M, et al. Synthetic hematocrit derived from the longitudinal relaxation of blood can lead to clinically significant errors in measurement of extracellular volume fraction in pediatric and young adult patients. J Cardiovasc Magn Reson. 2017;19(1):58.PubMedPubMedCentralCrossRef
66.
Pan JA, Lee YJ, Salerno M. Diagnostic performance of extracellular volume, native T1, and T2 mapping versus lake louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis. Circ Cardiovasc Imaging. 2018;11(7):e007598.PubMedPubMedCentralCrossRef
67.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–76.PubMedCrossRef
68.
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73.PubMedPubMedCentralCrossRef
69.
Filippetti L, Pace N, Marie PY. Cardiac Involvement After Recovering From COVID-19. JAMA Cardiol. 2021;6(2):243–4.PubMedCrossRef
70.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.PubMedPubMedCentralCrossRef
71.
Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserrat L, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802–8.PubMedCrossRef
72.
Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16(1):99.PubMedPubMedCentralCrossRef
73.
•• Cadour F, Quemeneur M, Biere L, Donal E, Bentatou Z, Eicher JC, et al. Prognostic value of cardiovascular magnetic resonance T1 mapping and extracellular volume fraction in nonischemic dilated cardiomyopathy. J Cardiovasc Magn Reson. 2023;25(1):7. This study demonstrates that elevated T1 and ECV are independent predictors of heart failure and arrythmias in patients with dilated cardiomyopathy.PubMedPubMedCentralCrossRef
74.
Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging. 2020;13(6):1299–310.PubMedPubMedCentralCrossRef
75.
Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89.PubMedPubMedCentralCrossRef
76.
He T, Smith GC, Gatehouse PD, Mohiaddin RH, Firmin DN, Pennell DJ. On using T2 to assess extrinsic magnetic field inhomogeneity effects on T2* measurements in myocardial siderosis in thalassemia. Magn Reson Med. 2009;61(3):501–6.PubMedCrossRef
77.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–9.PubMedCrossRef
78.
Ruberg FL, Miller EJ. Nuclear tracers for transthyretin cardiac amyloidosis time to bone up? Circulation-Cardiovascular Imaging. 2013;6(2):162–4.PubMedCrossRef
79.
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, et al. Radiopharmaceutical supply disruptions and the use of Tc-hydroxymethylene diphosphonate as an alternative to Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. J Nucl Cardiol. 2022;29(5):2748–60.PubMedPubMedCentralCrossRef
80.
Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413–7.PubMedCrossRef
81.
Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.PubMedPubMedCentralCrossRef
82.
Delbarre MA, Girardon F, Roquette L, Blanc-Durand P, Hubaut MA, Hachulla E, et al. Deep learning on bone scintigraphy to detect abnormal cardiac uptake at risk of cardiac amyloidosis. JACC Cardiovasc Imaging. 2023;16(8):1085–95.PubMedCrossRef
83.
Nichols KJ, Yoon SY, Van Tosh A, Palestro CJ. (99m)Tc-PYP SPECT and SPECT/CT quantitation for diagnosing cardiac transthyretin amyloidosis. J Nucl Cardiol. 2023;30(3):1235–45.PubMedCrossRef
84.
Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017;24(1):86–99.PubMedCrossRef
85.
Bois JP, Chareonthaitawee P. Continuing evolution in preparation protocols for (18)FDG PET assessment of inflammatory or malignant myocardial disease. J Nucl Cardiol. 2017;24(3):989–92.PubMedCrossRef
86.
Saric P, Young KA, Rodriguez-Porcel M, Chareonthaitawee P. PET imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers. Pharmaceuticals. 2021;14(12):1286.PubMedPubMedCentralCrossRef
87.
Bravo PE, Singh A, Di Carli MF, Blankstein R. Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2019;26(1):188–99.PubMedCrossRef
88.
Aitken M, Chan MV, Urzua Fresno C, Farrell A, Islam N, McInnes MDF, et al. Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and meta-analysis. Radiology. 2022;304(3):566–79.PubMedCrossRef
89.
Fukushima K, Nagao M, Yamamoto A, Serizawa N, Ishizaki U, Suzuki A, et al. Discrepancy between significant fibrosis and active inflammation in patients with cardiac sarcoidosis: combined and image fusion analysis of cardiac magnetic resonance and (18)F fluorodeoxyglucose positron emission tomography. Eur J Hybrid Imaging. 2019;3(1):9.PubMedPubMedCentralCrossRef
90.
Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2018;11(1):e007030.PubMedPubMedCentralCrossRef
91.
Subramanian M, Swapna N, Ali AZ, Saggu DK, Yalagudri S, Kishore J, et al. Pre-Treatment myocardial (18)FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging. 2021;14(10):2008–16.PubMedCrossRef
92.
Kim D, Collins JD, White JA, Hanneman K, Lee DC, Patel AR, et al. SCMR expert consensus statement for cardiovascular magnetic resonance of patients with a cardiac implantable electronic device. J Cardiovasc Magn Reson. 2024;26(1):100995.PubMedPubMedCentralCrossRef
93.
Peretto G, Busnardo E, Ferro P, Palmisano A, Vignale D, Esposito A, et al. Clinical applications of FDG-PET scan in arrhythmic myocarditis. Jacc-Cardiovascular Imaging. 2022;15(10):1771–80.PubMedCrossRef
94.
Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging. 2021;14(1):288–92.PubMedCrossRef
95.
Rigolli M, Anandabaskaran S, Christiansen JP, Whalley GA. Bias associated with left ventricular quantification by multimodality imaging: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000388.PubMedPubMedCentralCrossRef
96.
Barnea R, Agmon IN, Shafir G, Peretz S, Mendel R, Naftali J, et al. Cardiac CT for intra-cardiac thrombus detection in embolic stroke of undetermined source (ESUS). Eur Stroke J. 2022;7(3):212–20.PubMedPubMedCentralCrossRef
97.
Choi AD, Thomas DM, Lee J, Abbara S, Cury RC, Leipsic JA, et al. 2020 SCCT guideline for training cardiology and radiology trainees as independent practitioners (Level II) and advanced practitioners (Level III) in cardiovascular computed tomography: a statement from the society of cardiovascular computed tomography. J Cardiovasc Comput Tomogr. 2021;15(1):2–15.PubMedCrossRef
98.
Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–9.PubMedCrossRef
99.
Liddy S, Buckley U, Kok HK, Loo B, Glover B, Dhillon GR, et al. Applications of cardiac computed tomography in electrophysiology intervention. Eur Heart J Cardiovasc Imaging. 2018;19(3):253–61.PubMedCrossRef
100.
Bilchick KC, Mealor A, Gonzalez J, Norton P, Zhuo D, Mason P, et al. Effectiveness of integrating delayed computed tomography angiography imaging for left atrial appendage thrombus exclusion into the care of patients undergoing ablation of atrial fibrillation. Heart Rhythm. 2016;13(1):12–9.PubMedCrossRef
101.
Pathan F, Hecht H, Narula J, Marwick TH. Roles of transesophageal echocardiography and cardiac computed tomography for evaluation of left atrial thrombus and associated pathology: a review and critical analysis. JACC Cardiovasc Imaging. 2018;11(4):616–27.PubMedCrossRef
102.
Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020;22(2):184.PubMedCrossRef
103.
Galea R, Aminian A, Meneveau N, De Marco F, Heg D, Anselme F, et al. Impact of preprocedural computed tomography on left atrial appendage closure success: a swiss-apero trial subanalysis. JACC Cardiovasc Interv. 2023;16(11):1332–43.PubMedCrossRef
104.
Esposito A, Palmisano A, Antunes S, Maccabelli G, Colantoni C, Rancoita PMV, et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate: relationship between CT-segmented scar and electro-anatomic mapping. JACC Cardiovasc Imaging. 2016;9(7):822–32.PubMedCrossRef
105.
Alikhani Z, Li J, Merchan JA, Nijhof N, Mendel J, Orlov MV. Coronary sinus anatomy by computerized tomography, overlaid on live fluoroscopy can be successfully used to guide left ventricular lead implantation: a feasibility study. J Interv Card Electrophysiol. 2013;36(3):217–22.PubMedCrossRef
106.
Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al. The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report–2010. J Heart Lung Transplant. 2010;29(10):1089–103.PubMedCrossRef
107.
Pober JS, Chih S, Kobashigawa J, Madsen JC, Tellides G. Cardiac allograft vasculopathy: current review and future research directions. Cardiovasc Res. 2021;117(13):2624–38.PubMedPubMedCentral
108.
Wever-Pinzon O, Romero J, Kelesidis I, Wever-Pinzon J, Manrique C, Budge D, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63(19):1992–2004.PubMedCrossRef
109.
Li X, Kondray V, Tavri S, Ruhparwar A, Azeze S, Dey A, et al. Role of imaging in diagnosis and management of left ventricular assist device complications. Int J Cardiovasc Imaging. 2019;35(7):1365–77.PubMedCrossRef
110.
Tran BC, Nijjar PS. Role of contrast CT for the diagnosis and the prognosis of suspected LVAD thrombosis. J Card Surg. 2017;32(2):162–5.PubMedCrossRef
111.
Patel PA, Green CL, Lokhnygina Y, Christensen J, Milano CA, Rogers JG, et al. Cardiac computed tomography improves the identification of cardiomechanical complications among patients with suspected left ventricular assist device malfunction. J Cardiovasc Comput Tomogr. 2021;15(3):260–7.PubMedCrossRef
112.
Katsura M, Sato J, Akahane M, Kunimatsu A, Abe O. Current and novel techniques for metal artifact reduction at CT: practical guide for radiologists. Radiographics. 2018;38(2):450–61.PubMedCrossRef
113.
Thomas R, Aghayev A, Steigner ML. Artifactual appearance of thrombosis on using metal artifact reduction software reconstruction in computed tomographic angiography. J Comput Assist Tomogr. 2018;42(3):457–8.PubMedCrossRef
114.
Dilsizian V, Budde RPJ, Chen W, Mankad SV, Lindner JR, Nieman K. Best practices for imaging cardiac device-related infections and endocarditis: a JACC: cardiovascular imaging expert panel statement. JACC Cardiovasc Imaging. 2022;15(5):891–911.PubMedCrossRef
115.
Bravo PE, Di Carli MF, Dorbala S. Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Fail Rev. 2017;22(4):455–64.PubMedPubMedCentralCrossRef
116.
Bhatti S, Hakeem A, Yousuf MA, Al-Khalidi HR, Mazur W, Shizukuda Y. Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy. J Nucl Cardiol. 2011;18(3):407–20.PubMedCrossRef
117.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646.PubMedPubMedCentral
118.
Peper J, Becker LM, van den Berg H, Bor WL, Brouwer J, Nijenhuis VJ, et al. Diagnostic Performance of CCTA and CT-FFR for the Detection of CAD in TAVR Work-Up. JACC Cardiovasc Interv. 2022;15(11):1140–9.PubMedCrossRef
119.
Nous FMA, Geisler T, Kruk MBP, Alkadhi H, Kitagawa K, Vliegenthart R, et al. Dynamic myocardial perfusion CT for the detection of hemodynamically significant coronary artery disease. JACC Cardiovasc Imaging. 2022;15(1):75–87.PubMedCrossRef
Metadata
Title
The Role of Multimodality Imaging in Cardiomyopathy
Authors
Jonathan A. Pan
Amit R. Patel
Publication date
16-05-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 7/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02068-9

Other articles of this Issue 7/2024

Current Cardiology Reports 7/2024 Go to the issue

Cardiovascular Critical Care (A Higgins and R Lee, Section Editors)

Left Ventricular Unloading in Extracorporeal Membrane Oxygenation: A Clinical Perspective Derived from Basic Cardiovascular Physiology

New Therapies for Cardiovascular Disease (AA Bavry and M Massoomi, Section Editors)

Who benefits from PFO closure?

Cardiac PET, CT, and MRI (P Cremer, Section Editor)

Assessing Regurgitation Severity, Adverse Remodeling, and Fibrosis with CMR in Primary Mitral Regurgitation

Valvular Heart Disease (TL Kiefer, Section Editor)

Evaluation and Management of Mechanical Heart Valve Dysfunction and Thrombosis

Nuclear Cardiology (V Dilsizian, Section Editor)

Inflammation and Myocardial Blood Flow in Cardiac Sarcoidosis

Ischemic Heart Disease (D Mukherjee, Section Editor)

Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits